Stories

Kardium opens Globe registry to track outcomes after commercial launch

The company reports first enrollment at a Washington hospital, beginning planned follow-up of up to 500 patients across U.S. and Canadian sites without publishing registry outcomes yet.

KardiumBurnaby, British ColumbiaSources & technical notes
Kardium opens Globe registry to track outcomes after commercial launch
What matters

Key Takeaway

The company reports first enrollment at a Washington hospital, beginning planned follow-up of up to 500 patients across U.S. and Canadian sites without publishing registry outcomes yet.

Impacted Sectors

Editorial pillar: Other

Next Steps / Actionable Advice

Publication of seven-day safety and 12-month effectiveness results, plus identification of participating Canadian sites; the announcement provides no results-release date.

Kardium said in its October 21 announcement that Overlake Medical Center in Bellevue, Washington, activated the first Globe Registry site and enrolled its first patient. Participants will be followed for 12 months, starting evidence collection on the cardiac mapping and pulsed field ablation system in routine practice.

The prospective, post-approval registry is expected to enroll up to 500 patients across the United States and Canada. The ClinicalTrials.gov record identifies endpoints for treatment success at 12 months and major adverse events within seven days of ablation.

Globe combines high-density mapping and ablation in one catheter. CEO Kevin Chaplin and Overlake electrophysiology director Maheer Gandhavadi described encouraging early experience, but the announcement supplies no numerical outcomes supporting those observations. The single-arm observational design can document outcomes among treated patients; it cannot establish superiority over another system.

Evidence gathering accompanies manufacturing expansion. In its August funding announcement, Kardium reported federal support of up to $31.25 million toward a $125 million Vancouver project. That commitment concerns production capacity, not demonstrated clinical performance.

For electrophysiology leaders and medical-device investors, the next evidence is reported safety and 12-month effectiveness results, alongside confirmed Canadian participation. The registry record predates enrollment and still says “not yet recruiting”; the October announcement names only the Washington site.

Illustration generated with AI using Ollama. It does not depict a Kardium facility or the Globe device.

Sources & technical notes

Linked sources

Check the cited material to distinguish announcements from demonstrated results.

Evidence limit: First enrollment is company-reported, with no numerical registry outcomes published in the announcement. The single-arm observational design cannot establish comparative superiority, and the registry record predates enrollment.

What to evaluate next

This box highlights the systems, workflows, and decisions the article helps you assess.

  • Investors and electrophysiology leaders should assess reported safety, 12-month effectiveness and Canadian participation before treating registry enrollment as evidence supporting broader adoption.
  • Kardium said in its October 21 announcement that Overlake Medical Center in Bellevue, Washington, activated the first Globe Registry site and enrolled its first patient.
  • Operational lens: Integrated cardiac mapping and pulsed field ablation
Canadian PolicyAIAdvanced ManufacturingGovernance, Policy & Transactions
Read next

Related stories

View all stories